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Background
Morbidity and mortality from
cardiovascular diseases remains
on a high level all around the
world. The subsequence of ische-
mic heart disease that debuts
after an acute myocardial infarc-
tion or under the influence of
chronic ischemia is the develop-
ment of congestive heart failure.
Eventually cellular hypertrophy,
extracellular matrix remodeling
and dilatation of heart chambers
occur that led to ischemic cardio-
myopathy (ICMP) development.
ICMP is associated with poor
quality and shorter life expec-
tancy. To summarize, ICMP is
among of the most frequent rea-
sons of the human death [1–3].
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Перспективной является идея интрамиокардиальной трансплантации аутологичных прогени-
торных клеток периферической крови пациентам с ишемической кардиомиопатией (ИКМП), ко-
торые исчерпали возможности стандартных методов лечения. Пациенты с установленным диа-
гнозом ИКМП были разделены на две группы. В группе 1 (n=29) проводилась интрамиокарди-
альная трансплантация аутологичных прогениторных клеток периферической крови в комбинации
с оптимальной медикаментозной терапией. В группе 2 (n=31) назначалась только оптимальная
медикаментозная терапия. Во время контрольных обследований отмечено, что максимальный
эффект от трансплантации развивался через 6 мес. после процедуры. Фракция выброса лево-
го желудочка (ЛЖ) увеличилась в среднем на (6±3) %, улучшилась локальная и глобальная со-
кратимость миокарда ЛЖ. Через 18 мес. отмечено увеличение выживаемости в группе, где про-
водилась трансплантация.
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Background. Autologous peripheral blood progenitor cells transplantation (PBPCT) in patients
with ischemic cardiomyopathy (ICMP) who lack potentialities of standard treatment options seems to
have been perspective.
Aims. The main purpose of this study was decreasing of mortality and improving the quality of life
of patients with ICMP by developing and application in routine clinical practice the approach of in-
tramyocardial autologous PBPCT in combination with optimal drug therapy.
Materials and methods. Patients with diagnosed ICMP were divided into two groups: autologous
transplantation PBPCT in combination with optimal drug therapy (group 1, n=29) versus optimal drug
therapy alone (group 2, n=31). Patients of the group 1 received granulocyte colony-stimulating factor
(G-CSF) at a dose 5 мg/kg for 5 days. Leukapheresis was performed on the fifth day. Isolation of
mononuclear cells (MNC) was provided by Ficoll-Paque 1.077 g/ml density gradient centrifugation.
Intramyocardial transplantation was performed by NOGA XP Navigation System and Myostar cathe-
ter. Follow up occurred at 1, 3, 6, 12 and 18 months.
Results. During the follow up there was noticed that the maximum effect of intramyocardial trans-
plantation develoed after 6 months after the transplantation. LVEF increased by an average by (6±3)%
and improvement of local and global contractility observed. After 18 months-follow-up increasing of
survival was noticed.
Key words: progenitor cells, ischemich cardiomyopathy, intramyocardial transplantation, noga xp.
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Main approaches for treat-
ment of patients with ICMP that
exist are: drug treatment or sur-
gical intervention: mechanical re-
vascularization (bypass grafting
or percutaneous coronary inter-
vention) and heart transplanta-
tion. Surgical methods have
shown better outcomes compa-
rably with drug treatment. This
fact has been established in big
international multicenter rand-
omized trials [4]. Unfortunately,
a big group of patients for whom
surgical intervention is contrain-
dicated or this approach has not
been effective exists. Thus, it is
necessarily to develop a new
method of treatment of patients
with ischemic heart disease that
will provide an opportunity to in-
crease life expectancy compara-
bly to standard treatment options
[5].
The idea of autologous pe-
ripheral blood progenitor cells or
autologous bone marrow stem
cells transplantation in patients
with ICMP who lack potentialities
of standard treatment options
seems to have been perspec-
tive. According to the results of
preclinical in vitro studies periph-
eral blood progenitor and stem
cells are able to differentiate into
different types of cells and in car-
diomyocites in particular. In vivo
studies in animal models have
shown strong evidence of the
efficacy and safety of intramyo-
cardial and intracoronary trans-
plantation of autologous stem
cells of different types of myocar-
dial ischemia [6].
Also numerous clinical stud-
ies of the application of periphe-
ral blood and bone marrow stem
cells have been conducted re-
cently. They have shown the ef-
fectiveness of the intramyocar-
dial stem cell transplantation in
patients not only with myocardial
infarction and ischemic heart dis-
ease but also with idiopathic di-
lated cardiomyopathy [7].
Aims
The main purpose of this stu-
dy was decreasing of mortality
and improving the quality of life
for patients with ICMP by devel-
oping and application in routine
clinical practice the complex ap-
proach of intramyocardial autolo-
gous PBPCT in combination with
optimal drug therapy.
Materials and methods
This was open label controlled
randomized clinical trial. Main
inclusion criteria were: men and
women aged 40–80 with pre-
viously diagnosed ICMP with
LVEF <35% who were resistant
to optimal drug therapy at least
for three months before the en-
rolment and who were not can-
didate for surgical treatment (or
it was not effective). Main exclu-
sion criteria were: coronary ar-
tery bypass grafting or percuta-
neous coronary intervention with-
in 3 months, acute myocardial
infarction within 3 months, oncolo-
gy or hematology diseases with-
in 5 years, pregnancy (table 1).
Patients were divided into two
groups: intramyocardial trans-
plantation of autologous periph-
eral blood stem cells in combi-
nation with optimal drug therapy
(group 1, n=29) versus optimal
drug therapy alone (group 2,
n=31).
Patients of the group 1 re-
ceived granulocyte colony-stim-
ulating factor (G-CSF) at a dose
5 мg/kg for 5 days. Leukapher-
esis was performed on the fifths
day (Fresenius COM. TEC,
Germany) for collection of prima-
ry cytological material (PCM).
Isolation of mononuclear cells
was provided by Ficoll-Paque
1.077 g/ml (Sigma-Aldrich, UK)
density gradient centrifugation.
Obtained mononuclear cells
were concentrated in 0.9% sodi-
um chloride solution. Final cell
concentration must be no less
than 200⋅106 MNC per ml. In-
tramyocardial transplantation
was performed using NOGA XP
Navigation System and Myostar
catheter (Biosense Webster, USA).
The dose was divided into 18±3
injections of 0.2 ml per injection.
Follow up occurred at 1, 3, 6, 12
and 18 months or by patient’s
requirement.
Results
During G-CSF — treatment
common side effects were flu-
like symptoms and joint pains. It
was a tendency to worsening
angina pectoris symptoms that
resulted in increased demand in
nitrates. In one case severe chest
pain that contributed to addition-
al examination observed.
During leukapheresis com-
mon side effects were dizziness,
skin and mucous parastesias.
In two cases short period of
conscienceless was observed.
Mean volume of PCM was 153±
±23 ml.
All cell transplants after
the processing procedure con-
formed the requirements of the
protocol: they contained mini-
mum 200⋅106 cells per 1 ml, the
viability was no lower than 92%
and were not contaminated. For
the intramyocardial cell trans-
plantation 18±3 points were se-
lected (fig. 1). During the proce-
dure 11 cases of arrhythmias:
3 cases of ventricular fibrillation
Table 1
Some Baseline Characteristics of Patients
                 
Parameters
Group 1, Group 2, Рn=29 n=31
Median age, M±m 67±6 65±5 >0.05
Myocardial infarction, % 51.7 54.8 >0.05
LVEF, M±m 21±5 24±7 >0.05
Functional class, M±m 3.4±0.3 3.5±0.2 >0.05
Diabetes mellitus type II, % 27.6 24.3 >0.05
Hyperlipidemia, % 49.3 47.2 >0.05
Cerebral circulation disorders, % 3.5 2.1 >0.05
Peripheral vessel disease, % 8.2 8.1 >0.05
Chronic kidney disease, % 7.4 7.3 >0.05
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and 9 cases of ventricular tachy-
cardia and one case of AV-block
were observed during mapping
procedure and were not ob-
served during cell implantation.
Episodes of ventricular tachy-
cardia were short and resolved
without any intervention. In cas-
es of ventricular fibrillation defi-
brillation was applied success-
fully. In patient with AV-block
pacemaker was implanted im-
mediately.
During the follow up was no-
ticed that the maximum effect of
intramyocardial transplantation
developed after 6 months after
the transplantation. LVEF in-
creased by an average of 6±3%
and improvement of local and
global contractility observed. Af-
ter 18 months-follow-up it was
noticed the increasing of surviv-
al (fig. 2, table 2).
Discussing
Patients suffering from ICMP
with low LVEF (<35%) have ex-
tremely low life expectancy and
quality of life and increasing of
LVEF even on 5% (up to 40%)
is crucial. Usually people in this
cohort have exhausted potenti-
alities of drug as well as surgi-
cal methods of treatment. Al-
though these patients are somat-
ically unfit, intramyocardial trans-
plantation of autologous progen-
itor cells is to be not only safe
but also effective and cheap pro-
cedure for them.
Although during G-CSF treat-
ment worsening of angina pec-
toris symptoms and increased
demand in nitrates was ob-
served, these complications
were not life threatening. Appar-
ently those effects were related
to increased viscosity of blood
due to bone marrow stimulation.
They were not associated with
ST elevation or cardiac enzymes
elevations. In one case with se-
vere chest pain additional exam-
ination revealed L4-L5 pathology,
thus pain was related to com-
mon side effects of G-CSF ad-
ministration.
Leukapheresis is routinely
used in order to collect cells for
autologous or allogenic hemato-
poietic stem cell transplantation
in patients with hematological
diseases. In our study the proce-
dure of leukapheresis had some
differences. Because of low
LVEF loss of blood for extracor-
poral volume could be hemodi-
namicaly significant. Preventive
saline infusion could not be used
because of severe heart failure.
On the other hand citrate used
for the anticoagulation could lead
to hypocalcaemia and as a re-
sult to arrhythmias. Sometimes
allergic reactions could occur.
We provided leukapheresis
after premedication with de-
xamethasone and diphenilhid-
ramin in order to prevent side
effects. During the procedure
frequent side effects were: diz-
ziness, weakness, parastesias
and were related to mechanisms
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Fig. 2. Kaplan-Meier curves survival in both groups
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Fig. 1. Left ventricle NOGA XP Navigation System mapping: a —
a unipolar voltage map; b — ventricular contractility map. The spots mark
the site of implantation of progenitor cells
Table 2
Dynamics of some characteristics of LV’s function
 
Parameters
                   LVEF, %                       EDV, ml
Gr 1 Gr 2 Gr 1 Gr 2
Baseline 21±5 24±7 249±15 230±14
1 month 22±6 25±9 243±11 233±10
3 months 27±4* 27±7 239±14 239±13
6 months 29±5* 25±5 212±12* 237±12
12 months 28±6* 23.±4 210±16* 240±15
18 months 27±4* 22±8 224±14 243±17
Note. * — P<0.05.
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described above. Generally
these complications resolved
without any intervention. Only in
one case allergic reaction on cit-
rate observed. After GCS infu-
sion all symptoms resolved but
we were obliged to discontinue
the procedure. Thus, leukapher-
esis is safe procedure for somat-
ically unfit patients is preferable
than bone marrow aspiration for
obtaining progenitor cells but pa-
tients should be under continu-
ous medical staff supervision
during the procedure.
Protocols of treatment of ICMP
usually contain diuretics thus
patient are usually dehydrated.
Therefore hematocrit of primary
cytological material was high. As
a result hypercoagulation of PCM
observed. To prevent hyperco-
agulation we additionally added
citrate to PCM in ratio 1:10 rela-
tively before the processing.
Main advantage of the isolation
of mononuclear cells by density-
gradient centrifugation is low
cost; therefore this method could
be used to reduce expenses.
Eventually all patients sustained
the procedure successfully and
followed to the NOGA XP map-
ping procedure.
Electromechanical mapping
and intramyocardial progenitor
cells transplantation with NOGA
XP Navigation System is highly
precise method. Although during
NOGA XP mapping procedure
11 cases of arrhythmias were ob-
served they were not life threat-
ening and were observed only
during mapping procedure. Dur-
ing cells implantation none of
side effects were observed.
Conclusion
1. Method of the isolation of
autologous peripheral blood pro-
genitor cells in patients with
ICMP is safe procedure and give
an opportunity to obtain enough
amount of progenitor cells for the
intramyocardial implantation.
2. Intramyocardial autologous
peripheral blood progenitor cells
transplantation with NOGA XP
Navigation System is highly pre-
cise and reliable method.
3. Autologous peripheral blood
progenitor cells improve local
and global contractility of the left
ventricle, increase survival of
patients with ICMP.
4. Approach of autologous in-
tramyocardial peripheral blood
progenitor cell transplantation
advisable to perform to the pa-
tients with ischemic cardiomyo-
pathy that are resistant to stand-
ard treatment options.
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